273 related articles for article (PubMed ID: 31522079)
21. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
[TBL] [Abstract][Full Text] [Related]
22. Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer.
West H
Clin Chest Med; 2020 Jun; 41(2):249-258. PubMed ID: 32402360
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
24. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
25. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
[TBL] [Abstract][Full Text] [Related]
26. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
Guerrero E; Ahmed M
Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
[TBL] [Abstract][Full Text] [Related]
27. Review of treatment options for oligometastatic non-small cell lung cancer.
Folkert MR; Timmerman R
Clin Adv Hematol Oncol; 2015 Mar; 13(3):186-93. PubMed ID: 26352427
[TBL] [Abstract][Full Text] [Related]
28. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
30. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV
Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004
[TBL] [Abstract][Full Text] [Related]
31. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).
De Ruysscher D; Wanders R; Hendriks LE; van Baardwijk A; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
J Thorac Oncol; 2018 Dec; 13(12):1958-1961. PubMed ID: 30253974
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer.
Giraud N; Abdiche S; Trouette R
Cancer Radiother; 2019 Jul; 23(4):346-354. PubMed ID: 31130373
[TBL] [Abstract][Full Text] [Related]
33. From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?
Alongi F; Arcangeli S; Ramella S; Giaj-Levra N; Borghetti P; D'angelillo R; Ricchetti F; Maddalo M; Mazzola R; Trovò M; Russi E; Magrini SM;
Expert Rev Anticancer Ther; 2017 Feb; 17(2):157-165. PubMed ID: 27984919
[TBL] [Abstract][Full Text] [Related]
34. Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer.
Stephens SJ; Moravan MJ; Salama JK
J Oncol Pract; 2018 Jan; 14(1):23-31. PubMed ID: 29324212
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer.
Johnson KK; Rosen JE; Salazar MC; Boffa DJ
Ann Thorac Surg; 2016 Oct; 102(4):1166-71. PubMed ID: 27344278
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
37. [Multimodal Treatment of Non-Small Cell Lung Cancer with Cerebral Metastases].
Kudelin N; Bölükbas S; Schirren J
Zentralbl Chir; 2015 Jun; 140(3):328-33. PubMed ID: 26114639
[TBL] [Abstract][Full Text] [Related]
38. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.
Leonhardt CS; Stamm T; Hank T; Prager G; Strobel O
ESMO Open; 2023 Dec; 8(6):102067. PubMed ID: 37988953
[TBL] [Abstract][Full Text] [Related]
39. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
Kim KH; Lee J; Lee JI; Nam DH; Kong DS; Ahn YC; Park HC; Kwon OJ; Kim H; Chang MH; Yi SY; Ji SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2010 May; 68(2):258-63. PubMed ID: 19592127
[TBL] [Abstract][Full Text] [Related]
40. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Kroese TE; Bronzwaer S; van Rossum PSN; Schoppman SF; Deseyne PRAJ; van Cutsem E; Haustermans K; Nafteux P; Thomas M; Obermannova R; Mortensen HR; Nordsmark M; Pfeiffer P; Elme A; Adenis A; Piessen G; Bruns CJ; Lordick F; Gockel I; Moehler M; Gani C; Liakakos T; Reynolds JV; Morganti AG; Rosati R; Castoro C; Cellini F; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; van Berge Henegouwen MI; Hulshoff MCCM; van Dieren J; Vollebergh M; van Sandick JW; Jeene P; Muijs C; Slingerland M; Voncken FEM; Hartgrink H; Creemers GJ; van der Sangen MJC; Nieuwenhuijzen GAP; Berbee M; Verheij M; Wijnhoven B; Beerepoot LV; Mohammad NH; Mook S; Ruurda JP; Kolodziejczyk P; Polkowski WP; Wyrwicz L; Alsina M; Tabernero J; Pera M; Kanonnikoff TF; Cervantes A; Nilsson M; Monig S; Wagner AD; Guckenberger M; Griffiths EA; Smyth E; Hanna GB; Markar S; Chaudry MA; Hawkins MA; Cheong E; van Laarhoven HWM; van Hillegersberg R;
Eur J Cancer; 2024 Jun; 204():114062. PubMed ID: 38678762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
